Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review
<b>Background</b>: A combination of docetaxel and ramucirumab represents a standard of care in second-line treatment for patients with advanced NSCLC. Evidence of the regimen’s efficacy is based on the results of the REVEL trial conducted in the pre-immunotherapy (immune checkpoint inhibitors–ICIs)...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
MDPI AG
2025-11-01
|
| سلاسل: | Current Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mdpi.com/1718-7729/32/11/612 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|